Effect of unani formulation in Psoriasis
- Conditions
- Health Condition 1: L989- Disorder of the skin and subcutaneous tissue, unspecifiedHealth Condition 2: L400- Psoriasis vulgaris
- Registration Number
- CTRI/2022/08/044669
- Lead Sponsor
- Government Unani Medical College and Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Clinically diagnosed cases of up to moderate plaque psoriasis
Patients with PASI score less than 10
Patients with chronicity of psoriasis less than 2 years
Patients of all gender
Patients in age groups of 18 to 65 years
Willing and able to participate in the trial as an outpatient and comply with all trial requirements
Patients of Plaque psoriasis with PASI greater than 10
Patients with superadded skin infections like Eczema vitiligo Atopic dermatitis Contact dermatitis Tinea
Pregnant and lactating mothers
known case of renal insufficiency hepatic disorders and diabetes mellitus
Patient on treatment with corticosteroids and PUVA
Patients on medication with drugs that can aggravate psoriasis, like beta blockers calcium channel blockers or lithium
History or evidence of drug or alcohol abuse
Unwilling or unable to comply with the requirements of this protocol
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Reduction in PASI score PGA and Photographic lesionsTimepoint: 0th 15th 30th and 45th day
- Secondary Outcome Measures
Name Time Method Decrease in Psoriasis Quality of Life IndexTimepoint: 0th 15th 30th and 45th day